Patricia Haney

3.5k total citations
10 papers, 439 citations indexed

About

Patricia Haney is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Patricia Haney has authored 10 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Organic Chemistry and 4 papers in Oncology. Recurrent topics in Patricia Haney's work include Melanoma and MAPK Pathways (7 papers), Computational Drug Discovery Methods (4 papers) and Synthesis and biological activity (2 papers). Patricia Haney is often cited by papers focused on Melanoma and MAPK Pathways (7 papers), Computational Drug Discovery Methods (4 papers) and Synthesis and biological activity (2 papers). Patricia Haney collaborates with scholars based in United States, France and Australia. Patricia Haney's co-authors include Vicki Goodman, Axel Hauschild, Anne O’Hagan, Anne‐Marie Martin, Piotr Rutkowski, Lev Demidov, Jeffrey J. Legos, Jolly Mazumdar, Ademi Santiago-Walker and Michael Millward and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Patricia Haney

10 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patricia Haney United States	7	314	306	134	73	56	10	439
Karin Kemsley United Kingdom	4	363 1.2×	297 1.0×	71 0.5×	64 0.9×	56 1.0×	4	450
Michael Grondine United States	8	421 1.3×	265 0.9×	63 0.5×	67 0.9×	25 0.4×	14	544
Shivshankari Rajkumar Canada	5	310 1.0×	231 0.8×	82 0.6×	114 1.6×	48 0.9×	7	464
Sara Davenport United Kingdom	6	170 0.5×	225 0.7×	87 0.6×	73 1.0×	26 0.5×	9	422
Chenjing Xia China	4	439 1.4×	308 1.0×	49 0.4×	52 0.7×	70 1.3×	9	538
Julien Bollard France	8	241 0.8×	217 0.7×	60 0.4×	120 1.6×	48 0.9×	16	457
J. A. Sosman United States	13	403 1.3×	395 1.3×	31 0.2×	71 1.0×	75 1.3×	23	513
Donna-Michelle Smith United Kingdom	9	151 0.5×	213 0.7×	57 0.4×	100 1.4×	28 0.5×	12	363
Clarissa C. Yu Canada	5	450 1.4×	258 0.8×	53 0.4×	32 0.4×	86 1.5×	8	536
Guus J.J.E. Heynen Netherlands	10	375 1.2×	240 0.8×	121 0.9×	136 1.9×	13 0.2×	11	541

Countries citing papers authored by Patricia Haney

Since Specialization

Citations

This map shows the geographic impact of Patricia Haney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Haney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Haney more than expected).

Fields of papers citing papers by Patricia Haney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Haney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Haney. The network helps show where Patricia Haney may publish in the future.

Co-authorship network of co-authors of Patricia Haney

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Haney. A scholar is included among the top collaborators of Patricia Haney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Haney. Patricia Haney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Colombo, Nicoletta, Mary L. Disis, Keiichi Fujiwara, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS5600–TPS5600. 6 indexed citations

2.

Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations

3.

Ouellet, Danièle, Ekaterina Gibiansky, Anne O’Hagan, et al.. (2014). Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites. The Journal of Clinical Pharmacology. 54(6). 696–706. 57 indexed citations

4.

Grob, Jean‐Jacques, Mayur M. Amonkar, Salvador Martín‐Algarra, et al.. (2014). Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Annals of Oncology. 25(7). 1428–1436. 37 indexed citations

5.

Hauschild, Axel, Lev Demidov, Thomas Jouary, et al.. (2014). An Update on Overall Survival (Os) and Follow-On Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600E Mutation-Positive Metastatic Melanoma (Mm). Annals of Oncology. 25. iv378–iv378. 26 indexed citations

6.

Kieran, Mark W., Kenneth J. Cohen, François Doz, et al.. (2014). Complete radiographic responses in pediatric patients with BRAF^V600-positive tumors including high-grade gliomas: Preliminary results of an ongoing phase 1/2a safety and pharmacokinetics (PK) study of dabrafenib.. Journal of Clinical Oncology. 32(15_suppl). 10056–10056. 4 indexed citations

7.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2013). An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. Journal of Clinical Oncology. 31(15_suppl). 9013–9013. 89 indexed citations

8.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(15_suppl). LBA8500–LBA8500. 35 indexed citations

9.

Hauschild, Axel, Jean‐Jacques Grob, Lev Demidov, et al.. (2012). Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF^V600E-mutated melanoma.. Journal of Clinical Oncology. 30(18_suppl). LBA8500–LBA8500. 25 indexed citations

10.

Haney, Patricia, Richard Bihrle, & Kenyon K. Kopecky. (1992). Percutaneous Management of a Nephrocutaneous Fistula Due to a Pyelocaliceal Diverticular Calculus. The Journal of Urology. 148(3 Part 2). 1105–1107. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact